Chiesi USA, Inc.


Chiesi is a global biopharmaceutical group committed to research and development of innovative therapeutic solutions in respiratory health, rare diseases, and specialized care. As a Benefit Corporation and B Corp certified since 2019, Chiesi emphasizes sustainability, social impact, and environmental responsibility, aiming for net zero emissions by 2035. With over 85 years of experience, the company operates in 31 countries with more than 6,500 employees, and invests heavily in research, innovation, and sustainable practices.

Industries

biotechnology
medical
pharmaceutical

Nr. of Employees

Very Large (1000+)

Chiesi USA, Inc.

Parma, Emilia-Romagna, Italy, Europe


Products

Formoterol fumarate inhalation product

Inhaled bronchodilator formulation using formoterol fumarate; the product page references national prescribing information and regulatory summaries.

Inhaled tobramycin formulation

Inhaled antibiotic formulation using tobramycin for respiratory indications; product page links to regulatory summaries.

Pulmonary surfactant product (neonatology)

Exogenous pulmonary surfactant therapy used in neonatal respiratory distress management; product and clinical information are available via neonatal care pages.

Bronchitol (inhaled therapy product)

Product page referencing the national product monograph for up-to-date prescribing information; site advises contacting a healthcare professional for medical questions.


Services

Pharmacovigilance reporting service

Adverse-event intake and regulatory reporting channel for suspected drug reactions.

Medical information provision

Provision of regulated product and therapeutic information for clinicians and patients through controlled channels.

Clinical development and trial management

End-to-end clinical study services including protocol development, multi-phase trial execution, data transparency and decentralized trial components.

Biologics development and GMP manufacturing services

Integrated development and GMP manufacturing services for biologics, covering cell cultivation, upstream processing (250–2000 L), downstream processing, sterile fill–finish, packaging and small‑batch production for clinical and niche indications.

Partnering and open innovation programs

Structured partnering offerings for co-development, licensing and open-innovation collaborations, including digital-health partnerships.

Global commercialization and market access operations

Commercial and market access capabilities across multiple countries supported by a network of international affiliates.

View All Services

Expertise Areas

  • Clinical trial management and decentralized trials
  • Biologics discovery, development and translational R&D
  • GMP biomanufacturing with downstream fill–finish and packaging
  • Respiratory therapeutics and inhalation drug/device engineering
  • Show More (7)

Key Technologies

  • Monoclonal antibody and recombinant protein development
  • Upstream bioprocessing (250–2000 L scale)
  • Flexible small-batch biologics manufacturing
  • Sterile fill–finish and packaging processes
  • Show More (9)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.